title: Response to Comment on Erondu et al. Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program. Diabetes Care 2015;38:1680-1686.
authors.affiliation: Janssen Research & Development, LLC, Raritan, NJ.
authors.forename: Ngozi
authors.initials: N
authors.lastname: Erondu
authors.affiliation: Janssen Research & Development, LLC, Raritan, NJ.
authors.forename: Mehul
authors.initials: M
authors.lastname: Desai
authors.affiliation: Janssen Research & Development, LLC, Raritan, NJ.
authors.forename: Kirk
authors.initials: K
authors.lastname: Ways
authors.affiliation: Janssen Research & Development, LLC, Raritan, NJ gmeining@its.jnj.com.
authors.forename: Gary
authors.initials: G
authors.lastname: Meininger
mesh_terms: D000068896:Canagliflozin / Q000009:adverse effects*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D016883:Diabetic Ketoacidosis / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D008297:Male
chemical_list: D007004:Hypoglycemic Agents; D000068896:Canagliflozin